Last Price$177.02.3%
Market Cap$19.6B
LTM Cash Return on Invested Capital (CROIC)
6.4%
5Y avg
11.3%
Medical - Diagnostics & Research industry
median
(13.1%)
Stock quality & Intrinsic value
6/10
1.1% undervalued
Quest Diagnostics Incorporated Cash Return on Invested Capital (CROIC)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Return on Invested Capital (CROIC) | 19.5% | 11.3% | 11.8% | 11.1% | 11.1% | 11.1% | 12.3% | 9.3% | 12.3% | 5.3% | 7.5% | 6.3% | 9.0% | 10.2% | 8.4% | 8.2% | 14.3% | 15.6% | 11.1% | 7.2% |
Overvalued or undervalued?
Check the intrinsic value for DGX
and see if it's the right time to invest.
Quest Diagnostics Incorporated (DGX) Cash Return on Invested Capital (CROIC) comparison analysis
General
LTM Cash Return on Invested Capital (CROIC)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Quest Diagnostics IncorporatedDGX
6.4%
(6.4%)
(6.5%)
9.2%
Median Peer Set
13.0%
(0.3%)
(2.7%)
15.2%
IDEXX Laboratories, Inc.IDXX
43.4%
8.7%
25.2%
23.1%
Mettler-Toledo International Inc.MTD
42.0%
2.2%
12.7%
22.3%
Illumina, Inc.ILMN
18.6%
(2.9%)
4.6%
(28.0%)
Waters CorporationWAT
16.7%
(0.5%)
(7.9%)
21.7%
Agilent Technologies, Inc.A
16.5%
(4.7%)
5.0%
19.8%
IQVIA Holdings Inc.IQV
9.6%
2.8%
2.4%
8.9%
Thermo Fisher Scientific Inc.TMO
8.6%
(4.6%)
(12.4%)
14.0%
Danaher CorporationDHR
7.6%
(0.1%)
(17.9%)
16.3%
Laboratory Corporation of America HoldingsLH
7.4%
(18.3%)
(65.8%)
3.4%
Natera, Inc.NTRA
(6.1%)
32.0%
(32.1%)
(40.2%)
DGX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 5,126.6 0.0% | 5,503.7 7.4% | 6,268.7 13.9% | 6,704.9 7.0% | 7,249.4 8.1% | 7,455.2 2.8% | 7,368.9 (1.2%) | 7,510.5 1.9% | 7,382.6 (1.7%) | 7,146.0 (3.2%) | 7,435.0 4.0% | 7,493.0 0.8% | 7,515.0 0.3% | 7,709.0 2.6% | 7,531.0 (2.3%) | 7,726.0 2.6% | 9,437.0 22.1% | 10,788.0 14.3% | 9,883.0 (8.4%) | 9,252.0 (6.4%) |
| Cost of Goods Sold (COGS) | 2,990.7 | 3,257.3 | 3,696.0 | 3,969.8 | 4,256.1 | 4,321.5 | 4,317.2 | 4,395.3 | 4,364.7 | 4,326.0 | 4,637.0 | 4,657.0 | 4,616.0 | 4,719.0 | 4,926.0 | 5,037.0 | 5,804.0 | 6,579.0 | 6,450.0 | 6,291.0 |
% margin | 2,135.9 41.7% | 2,246.4 40.8% | 2,572.7 41.0% | 2,735.1 40.8% | 2,993.3 41.3% | 3,133.7 42.0% | 3,051.7 41.4% | 3,115.2 41.5% | 3,017.9 40.9% | 2,820.0 39.5% | 2,798.0 37.6% | 2,836.0 37.8% | 2,899.0 38.6% | 2,990.0 38.8% | 2,605.0 34.6% | 2,689.0 34.8% | 3,633.0 38.5% | 4,209.0 39.0% | 3,433.0 34.7% | 2,961.0 32.0% |
| Operating Expenses | 1,234.4 | 1,278.3 | 1,444.6 | 1,643.7 | 1,770.9 | 1,774.6 | 1,756.2 | 2,120.2 | 1,817.1 | 1,819.0 | 1,815.0 | 1,771.0 | 1,740.0 | 1,825.0 | 1,500.0 | 1,458.0 | 1,662.0 | 1,828.0 | 2,005.0 | 1,761.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,227.7 | 1,257.8 | 1,433.7 | 1,612.9 | 1,736.9 | 1,747.6 | 1,707.7 | 1,814.3 | 1,745.2 | 1,704.0 | 1,728.0 | 1,679.0 | 1,681.0 | 1,750.0 | 1,424.0 | 1,457.0 | 1,550.0 | 1,727.0 | 1,874.0 | 1,615.0 |
% margin | 901.4 17.6% | 968.1 17.6% | 1,128.0 18.0% | 1,091.3 16.3% | 1,222.4 16.9% | 1,359.1 18.2% | 1,295.5 17.6% | 995.0 13.2% | 1,200.8 16.3% | 1,475.0 20.6% | 983.0 13.2% | 1,399.0 18.7% | 1,277.0 17.0% | 1,165.0 15.1% | 1,101.0 14.6% | 1,231.0 15.9% | 1,971.0 20.9% | 2,381.0 22.1% | 1,428.0 14.4% | 1,262.0 13.6% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 2.5 | 1.4 | 2.8 | 3.0 | 3.0 | 3.0 | 1.0 | 1.0 | 2.0 | 2.0 | 5.0 | 3.0 | 1.0 | 10.0 | 11.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 185.5 | 144.1 | 146.1 | 170.6 | 164.7 | 159.0 | 164.0 | 153.0 | 143.0 | 151.0 | 167.0 | 175.0 | 163.0 | 151.0 | 138.0 | 163.0 |
| Pre-tax Income | 835.1 | 910.5 | 1,033.3 | 912.4 | 1,019.0 | 1,227.9 | 1,184.3 | 856.3 | 1,068.4 | 1,348.0 | 849.0 | 1,103.0 | 1,086.0 | 1,030.0 | 926.0 | 1,076.0 | 1,884.0 | 2,599.0 | 1,235.0 | 1,130.0 |
% effective tax rate | 335.9 40.2% | 364.2 40.0% | 407.6 39.4% | 358.6 39.3% | 386.8 38.0% | 460.4 37.5% | 425.5 35.9% | 349.0 40.8% | 401.9 37.6% | 500.0 37.1% | 262.0 30.9% | 373.0 33.8% | 429.0 39.5% | 241.0 23.4% | 182.0 19.7% | 247.0 23.0% | 460.0 24.4% | 597.0 23.0% | 264.0 21.4% | 248.0 21.9% |
% margin | 499.2 9.7% | 546.3 9.9% | 586.4 9.4% | 339.9 5.1% | 581.5 8.0% | 729.1 9.8% | 720.9 9.8% | 470.6 6.3% | 555.7 7.5% | 849.0 11.9% | 556.0 7.5% | 709.0 9.5% | 645.0 8.6% | 772.0 10.0% | 736.0 9.8% | 858.0 11.1% | 1,431.0 15.2% | 1,995.0 18.5% | 946.0 9.6% | 854.0 9.2% |
| EPS | 2.45 | 2.71 | 2.98 | 1.76 | 2.99 | 3.91 | 4.08 | 2.95 | 3.49 | 5.58 | 3.83 | 4.92 | 4.58 | 5.63 | 5.41 | 6.38 | 10.68 | 15.90 | 8.12 | 7.59 |
| Diluted EPS | 2.35 | 2.66 | 2.94 | 1.74 | 2.97 | 3.87 | 4.05 | 2.92 | 3.46 | 5.54 | 3.81 | 4.87 | 4.51 | 5.50 | 5.29 | 6.29 | 10.52 | 15.53 | 7.98 | 7.52 |
% margin | 1,049.6 20.5% | 1,183.7 21.5% | 1,325.4 21.1% | 1,329.2 19.8% | 1,500.7 20.7% | 1,631.2 21.9% | 1,585.8 21.5% | 1,302.0 17.3% | 1,523.0 20.6% | 1,793.0 25.1% | 1,304.0 17.5% | 1,555.0 20.8% | 1,479.0 19.7% | 1,453.0 18.8% | 1,404.0 18.6% | 1,585.0 20.5% | 2,411.0 25.5% | 3,159.0 29.3% | 1,820.0 18.4% | 1,732.0 18.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Quest Diagnostics Incorporated's Cash Return on Invested Capital (CROIC)?
As of today, Microsoft Corp's last 12-month Cash Return on Invested Capital (CROIC) is 6.4%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Cash Return on Invested Capital (CROIC) for Quest Diagnostics Incorporated have been 11.1% over the past three years, and 11.9% over the past five years.
2) Is Quest Diagnostics Incorporated's Cash Return on Invested Capital (CROIC) Good?
As of today, Quest Diagnostics Incorporated's Cash Return on Invested Capital (CROIC) is 6.4%, which is higher than industry median of (13.1%). It indicates that Quest Diagnostics Incorporated's Cash Return on Invested Capital (CROIC) is Good.